SRPT Today - Jul 14: Court Ruling Stings

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

SRPT Today - Jul 14: Court Ruling Stings

無料で聴く

ポッドキャストの詳細を見る

Hey, what’s up? I’m Joey, a longtime investor here to break down what went down today with Sarepta, or SRPT. Spoiler alert: it was a red day, down about 3%.

So, here’s the scoop. The stock got smoked, dropping almost 3% today. It was a pretty quiet day overall, with volume way below average, so not a ton of action. But the big reason for the dip? A court just revived a patent lawsuit against them from Regenxbio. Yeah, that one stung. This lawsuit is about their muscular disorder therapy, and it’s just another hurdle for Sarepta as they try to push their treatments forward.

Why does this matter? Well, investors are super sensitive to legal issues, especially when it comes to patents. If the court sides with Regenxbio, it could really mess with Sarepta's plans and future earnings. Plus, there’s been chatter about whether Sarepta is still undervalued after their recent FDA sNDA acceptance for DMD therapies. But with this lawsuit looming, it’s tough for folks to feel confident. It’s like trying to enjoy a sunny day when a storm cloud is hanging over you, you know?

On the horizon, there’s still some hope for Sarepta. The FDA acceptance for their DMD therapies is a big deal, and if they can navigate through the legal mess, that could change the game for them. But until then, it’s a bit of a rough ride.

So, that’s the lowdown on SRPT today. Just remember, this is all for your info and entertainment. I’m not here to give financial advice, just sharing what’s happening. Catch you later!

まだレビューはありません